Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases.

CONCLUSION: Overall efficacy of canakinumab was 93.1% in this study. No major adverse event was observed under canakinumab treatment. Canakinumab seems to be effective and safe in children with rheumatic diseases. PMID: 32419407 [PubMed - in process]
Source: The Turkish Journal of Pediatrics - Category: Pediatrics Authors: Tags: Turk J Pediatr Source Type: research